Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-03

Clinical Trial Update: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial of acalabrutinib for untreated chronic lymphocytic leukemia is ongoing. The study status is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Untreated Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING